An understanding of the interplay between the DOX-treated cells and the tumor microenvironment seems crucial for the development of combinatorial regimens including immune checkpoint inhibitors such as PD-L1 antibodies and DOX [231]. The gene discussed is CD274; the disease is neoplasm.